Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
251
Ross Stores
ROST
$74B
| $236M | 0.06% |
1,309,994
+24,403
| +2% | +$4.07M |
2013 Q2
50 quarters
|
|
252
State Street Technology Select Sector SPDR ETF
XLK
$131B
| $235M | 0.06% |
1,635,404
-75,426
| -4% | -$10.9M |
2013 Q2
50 quarters
|
|
253
PUT
State Street Utilities Select Sector SPDR ETF
XLU
$21B
| $235M | 0.06% |
5,510,400
+4,941,200
| +868% | +$219M |
2024 Q3
5 quarters
|
|
254
PUT
Nike
NKE
$49.4B
| $233M | 0.06% |
3,659,000
+2,696,100
| +280% | +$176M |
2024 Q3
5 quarters
|
|
|
CYBR
255
DELISTED
CyberArk
CYBR
| $232M | 0.06% |
520,287
+48,876
| +10% | +$23.5M |
2015 Q2
42 quarters
|
|
256
PNC Financial Services
PNC
$88.7B
| $231M | 0.06% |
1,104,499
-213,368
| -16% | -$41.2M |
2013 Q2
50 quarters
|
|
257
State Street SPDR S&P Biotech ETF
XBI
$10.5B
| $230M | 0.06% |
1,890,408
-113,939
| -6% | -$13.1M |
2013 Q2
50 quarters
|
|
258
Biogen
BIIB
$32.8B
| $230M | 0.06% |
1,305,007
-54,417
| -4% | -$8.89M |
2013 Q2
50 quarters
|
|
259
Union Pacific
UNP
$164B
| $228M | 0.05% |
986,618
-73,981
| -7% | -$16.9M |
2013 Q2
50 quarters
|
|
260
McKesson
MCK
$103B
| $226M | 0.05% |
275,089
-164,734
| -37% | -$134M |
2013 Q2
50 quarters
|
|
261
CALL
iShares China Large-Cap ETF
FXI
$3.97B
| $225M | 0.05% |
5,878,700
-18,369,800
| -76% | -$729M |
2023 Q4
8 quarters
|
|
262
Etsy
ETSY
$6.75B
| $224M | 0.05% |
4,041,220
+251,373
| +7% | +$15.3M |
2015 Q2
42 quarters
|
|
|
263
PUT
iShares China Large-Cap ETF
FXI
$3.97B
| $221M | 0.05% |
5,758,700
-3,377,500
| -37% | -$134M |
2024 Q3
5 quarters
|
|
264
Fortinet
FTNT
$134B
| $219M | 0.05% |
2,759,387
-1,018,579
| -27% | -$84.5M |
2016 Q2
38 quarters
|
|
265
Cintas
CTAS
$77.7B
| $218M | 0.05% |
1,159,178
+226,113
| +24% | +$42.6M |
2013 Q2
50 quarters
|
|
266
The Kraft Heinz Company
KHC
$26.6B
| $218M | 0.05% |
8,973,146
+3,926,141
| +78% | +$97.7M |
2015 Q3
41 quarters
|
|
267
PUT
State Street SPDR S&P Regional Banking ETF
KRE
$3.63B
| $217M | 0.05% |
3,355,000
+2,213,200
| +194% | +$139M |
2024 Q3
5 quarters
|
|
268
CVS Health
CVS
$111B
| $217M | 0.05% |
2,730,227
-1,648,988
| -38% | -$130M |
2013 Q2
50 quarters
|
|
269
Medtronic
MDT
$111B
| $215M | 0.05% |
2,240,964
-4,590,239
| -67% | -$446M |
2013 Q2
50 quarters
|
|
270
Seagate
STX
$189B
| $215M | 0.05% |
779,811
+219,245
| +39% | +$56.9M |
2022 Q1
15 quarters
|
|
271
Colgate-Palmolive
CL
$67.4B
| $213M | 0.05% |
2,695,237
-280,839
| -9% | -$22M |
2013 Q2
50 quarters
|
|
272
Equinix
EQIX
$101B
| $212M | 0.05% |
276,854
-24,117
| -8% | -$18.9M |
2013 Q2
50 quarters
|
|
273
PUT
Oracle
ORCL
$436B
| $211M | 0.05% |
1,084,700
+84,200
| +8% | +$20M |
2025 Q2
2 quarters
|
|
274
PACCAR
PCAR
$57.9B
| $208M | 0.05% |
1,902,898
-589,735
| -24% | -$60.4M |
2013 Q2
50 quarters
|
|
275
Credo Technology Group
CRDO
$42.8B
| $208M | 0.05% |
1,448,004
+365,923
| +34% | +$56.3M |
2022 Q1
15 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.